Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab.
Yi-Qun CheYue ZhangDi WangHui-Ying LiuDi ShenYang LuoPublished in: Drug design, development and therapy (2019)
Our data indicate that baseline ALC value of ≤1 G/L is a predictor of poor outcomes, but not of response, in patients with MBC treated with trastuzumab.